Factors Associated with Severe Late Toxicity After Concurrent Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis by Machtay, MD, Mitchell et al.
Bodine Journal
Volume 1 | Issue 1 Article 7
2016
Factors Associated with Severe Late Toxicity After
Concurrent Chemoradiation for Locally Advanced
Head and Neck Cancer: An RTOG Analysis
Mitchell Machtay, MD
Thomas Jefferson University, mitchell.machtay@jefferson.edu
Jennifer Moughan, MS
RTOG Headquarters and Statistical Center and the American College of Radiology, Philadelphia
Andrew Trotti, MD
Moffitt Cancer Center of University of South Florida, Tampa
Adam S. Garden, MD
MD Anderson Cancer Center, Houston
Randal S. Weber, MD
MD Anderson Cancer Center, Houston
See next page for additional authors
Follow this and additional works at: http://jdc.jefferson.edu/bodinejournal
Part of the Oncology Commons
Let us know how access to this document benefits you
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
Bodine Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Machtay, MD, Mitchell; Moughan, MS, Jennifer; Trotti, MD, Andrew; Garden, MD, Adam S.; Weber, MD, Randal S.; Cooper, MD, Jay
S.; Forastiere, MD, Arlene; and Ang, MD, K. Kian (2016) "Factors Associated with Severe Late Toxicity After Concurrent
Chemoradiation for Locally Advanced Head and Neck Cancer: An RTOG Analysis," Bodine Journal: Vol. 1: Iss. 1, Article 7.
Available at: http://jdc.jefferson.edu/bodinejournal/vol1/iss1/7
Factors Associated with Severe Late Toxicity After Concurrent
Chemoradiation for Locally Advanced Head and Neck Cancer: An
RTOG Analysis
Authors
Mitchell Machtay, MD; Jennifer Moughan, MS; Andrew Trotti, MD; Adam S. Garden, MD; Randal S. Weber,
MD; Jay S. Cooper, MD; Arlene Forastiere, MD; and K. Kian Ang, MD
This article is available in Bodine Journal: http://jdc.jefferson.edu/bodinejournal/vol1/iss1/7
BODINEJOURNAL34
Factors Associated with Severe Late 
Toxicity After Concurrent Chemoradiation 
for Locally Advanced Head and Neck 
Cancer: An RTOG Analysis
Purpose
Concurrent chemoradiotherapy (CCRT) for squamous cell carcinoma of the head and neck 
(SCCHN) increases both local tumor control and toxicity. This study evaluates clinical factors that 
are associated with and might predict severe late toxicity after CCRT.
Methods
Patients were analyzed from a subset of three previously reported RTOG trials of concurrent 
chemoradiotherapy for locally advanced SCCHN (RTOG 91-11; 97-03; and 99-14). Severe late 
toxicity was defined in this secondary analysis as chronic Grade 3-4 pharyngeal/laryngeal toxicity 
(RTOG/EORTC late toxicity scoring system) and/or requirement for a feeding tube ≥2 years after 
registration and/or potential treatment-related death (e.g. pneumonia) within 3 years. Case-control 
analysis was performed, with a multivariable logistic regression model that included pre-treatment 
and treatment potential factors.
Results
A total of 230 patients were evaluable for this analysis, 99 cases (patients with severe late toxicities) 
and 131 controls; thus 43% of evaluable patients had a severe late toxicity. On multivariable analysis, 
significant variables correlated with the development of severe late toxicity were older age (odds ratio 
1.05 per year; p = 0.001); advanced T-stage (odds ratio 3.07; p=0.0036); larynx/hypopharynx primary 
site (odds ratio 4.17; p=0.0041); and neck dissection after chemo-RT (odds ratio 2.39; p=0.018).  
Conclusions
Severe late toxicity following CCRT is common. Older age, advanced T-stage, and larynx/
hypopharynx primary site were strong independent risk factors. Neck dissection after CCRT was 
associated with an increased risk of these complications.
Background/Introduction 
Concurrent chemoradiotherapy (CCRT) is a standard treatment for patients with locally advanced 
squamous cell carcinoma of the head and neck (SCCHN) treated non-surgically.  Meta-analyses 
show an improved 5-year survival by approximately 8% when CCRT is compared to radiotherapy 
alone1, 2. The advantage of this approach with respect to disease free survival and local-regional 
control is greater than 8%3-6, 7-10.
While there are undisputed advantages to CCRT for local-regional control, it increases toxicity 
when compared to radiotherapy alone11. Many studies have focused on acute toxicity, particularly 
mucositis, as summarized in a meta-analysis 
by Trotti et al.12. Comprehensive data on late 
toxicity from randomized trials of RT +/- 
chemotherapy, however, are sparse. Late toxicity 
may include long-term severe dysphagia and 
its related effects, including dependence upon 
a feeding tube, and have a profound effect on 
quality of life. The increased incidence of these 
serious, potentially permanent effects after 
CCRT is concerning, leading some to question 
as to whether chemoradiotherapy is truly a 
major improvement in the therapeutic ratio 
over radiotherapy alone.13
Starting approximately 15 years ago, the RTOG 
conducted a series of prospective clinical trials 
using CCRT for locally advanced SCCHN. 
General data on efficacy and early and subacute 
toxicity have been reported14-16. It is likely, 
however, that each individual study is 
underpowered for a thorough analysis of late 
effects, given sample size and patient attrition 
due to mortality and other causes. Consequently, 
we performed a secondary analysis of severe late 
toxicities from these several trials, specifically 
focusing on late toxicities and mortality related 
to pharyngolaryngeal dysfunction.  An analysis 
of potential factors associated with severe late 
toxicities was undertaken.
Materials/Methods
As noted above, the three prospective trials 
analyzed for this paper have been previ-
ously reported. All three studies required an 
acceptable performance status (60-100% by 
Karnofsky scale); non-metastatic stage III/IV 
SCCHN; and good hematologic, renal, hepatic 
and cardiovascular function.
Briefly, the three studies are:
RTOG 91-1114: A phase III trial of larynx-
preserving radiotherapy or chemoradiotherapy 
for selected Stage III/IV larynx cancer. For
this analysis, only the concurrent chemo-
radiotherapy arm was studied; this treatment 
in this arm consisted of 70 Gy in convention-
ally fractionated radiotherapy (XRT) – 2 Gy 
once daily – plus three cycles of high dose
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RTOG Analysis
cisplatin (100 mg/m2, Weeks 1, 4, and 7). There were 172 patients in 
this arm from RTOG 91-11; 88 patients were evaluable for this analysis 
of late toxicity. 
RTOG 97-0317:  A Phase IIR trial of several novel regimens of concur-
rent chemoradiotherapy for stage III/IV head and neck cancer (excluding 
patients who were eligibile for RTOG 91-11). This study included three 
arms. Arms 1 and 3 utilized conventionally fractionated XRT as per 91-
11. Arm 1 chemotherapy was infusional 5-FU and cisplatin, both given 
daily during the last two weeks of XRT. Arm 3 chemotherapy was once 
weekly cisplatin (20 mg/m2/week) and paclitaxel (30 mg/m2/week). 
Arm 2 chemoradiotherapy was modeled upon the prospective phase 
II trials performed by the University of Chicago. In Arm 2, although 
the total XRT dose remained 70 Gy in 2 Gy fractions, it was delivered 
over 13 weeks (week-on, week-off technique); chemotherapy in Arm 2 
consisted of concurrent infusional 5-FU and hydroxyurea. There were 
231 patients in RTOG 97-03; 102 patients were evaluable for this analysis 
of late toxicity.
RTOG 99-1416: A Phase II trial of accelerated radiotherapy with 
concurrent chemotherapy for stage III/IV head and neck cancer. This 
single arm phase II study consisted of accelerated concomitant boost 
radiotherapy to 72 Gy over 6 weeks (as per the concomitant boost arm of 
RTOG 90-03), with two cycles of high dose cisplatin (100 mg/m2 weeks 1 
and 4). There were 76 patients in RTOG 99-14; 40 patients were evaluable 
for this analysis of late toxicity.
All of these studies used conventional radiotherapy techniques, mostly 
2-dimensional planning and delivery. No patient received intensity 
modulated radiation therapy (IMRT). For this report, a severe late 
toxicity was defined as any or all of the following events:
•  Grade 3 or greater toxicity (RTOG/EORTC Late Toxicity Criteria) 
present > 180 days after the start of XRT and clearly related to 
dysfunction of the larynx and/or pharynx (e.g. dysphagia)
•  Requirement for a feeding tube/gastrostomy 2 years or longer after the 
start of XRT. 
• Death without cancer progression and from an uncertain cause in 
which laryngeal dysfunction is suspected to be a contributing factor 
(e.g. pneumonia) ≤ 3 years from the date of randomization. Patients 
who died of unknown causes were included in this category. Review 
of these deaths was performed by one of the study authors (MM) in 
a manner blinded to any of the patient’s clinical pre-treatment and/or 
treatment related characteristics. 
Patients who suffered one or more qualifying severe late toxicity events 
were only considered to be one “case.”
Patients with severe laryngopharynx dysfunction due to cancer, prior to 
the start of treatment, were excluded because of the potential confounding 
nature of tumor destruction of critical normal tissues (See Table 1). In 
RTOG 91-11, the determination of severe pre-treatment laryngopharynx 
dysfunction was based on patients’ on-study data collection form, which 
scored airway obstruction and dysphagia on a 4-point scale (none, mild, 
moderate, severe/life-threatening); patients with severe/life-threatening 
airway obstruction and/or dysphagia based on this form were excluded. 
In RTOG 91-11, data on pre-treatment use of feeding tubes were not 
collected. In RTOG 97-03 and RTOG 99-14, pre-treatment feeding tube 
data were collected, and this was used as the primary means of defining 
patients with pre-treatment severe laryngopharynx dysfunction.  
Patients with missing/inevaluable data or early death from acute toxicity 
were also excluded.
Statistical Analysis
Frequency tables with counts and percentages were used to describe 
pretreatment and treatment characteristics for each group.  Univariate 
and multivariable logistic regression models were used to identify 
associations of pretreatment and treatment-related factors with severe 
late toxicity.  All models were stratified by the 5 treatment arms described 
above.  The following factors were studied: age (continuous variable); 
gender; race (non-black vs. black); KPS (60-80 vs. 90-100); hemoglobin 
(continuous variable); weight loss pre-treatment (continuous variable); 
T-stage (T1/2 vs. T3/4); N Stage (Nx/0/1 vs. N2 vs. N3); Tumor site 
(oral cavity/oropharynx vs. larynx/hypopharynx); radiotherapy dose 
received as assessed by late effects BED model (total RT dose multiplied 
by (1+ [dose/fraction size] ÷ 3): continuous variable); chemotherapy 
dose received (<85% of planned dose vs. > 85% of planned dose); and 
post-RT neck dissection (yes vs. no).  Variables’ levels were grouped in 
order to avoid small cell counts.  A stepwise selection procedure was 
used to build the multivariable logistic regression model using the above 
pretreatment/treatment variables.  Entry criterion was set at p < 0.05. 
The odds ratios (OR) for each variable in the final model along with 
their 95% confidence intervals and p-values are reported.  The odds 
ratios estimate how much more (less) likely it is to be in the case group 
versus the control group among patients with the specific variable level’s 
characteristic compared to those patients in the reference level (RL), after 
stratifying for treatment arm. The cumulative incidence method was 
used to estimate time to severe late toxicity and levels for pre-treatment/
treatment-related variables were compared using the Gray’s test 18, 19.
Table 1. Summary of Patients Excluded from this Analysis
RTOG 91-11 
(Original 
N=172)
RTOG 97-03 
(Original 
N=231)
RTOG 99-14 
(Original 
N=76)
Total
(Original 
N=479)
Reason for Exclusion 
Severe Pre-treatment  15 — — 15
Airway Obstruction
Severe Pre-treatment  5 — — 5
Dysphagia
Pre-treatment Feeding  — 62 18 80
Tube Dependence
Total Excluded due to  20 62 18 100
Severe pre-treatment 
laryngopharynx 
dysfunction
Death from Acute  2 3 1 6
toxicity
Tumor Recurrence/ 52 62 16 130
death < 3 yrs followup.
Missing Data 10 2 1 13
Grand Total Excluded 84 129 36 249
Total Analyzable  88 102 40 230
for this study
Abbreviations as in Table 4.
Reference level: GTV ≤45 cm3, dose 90.3 Gy.
*Chi-square test using Cox proportional hazards model.
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Results
The original, potential patient population from these three studies was 
479. However, there were 130 patients excluded because of local-regional 
failure or death due to cancer, 100 patients excluded because of severe 
pre-treatment laryngopharynx dysfunction due to tumor, 13 patients 
excluded because of missing data, and 6 patients excluded because of 
early death due to acute toxicity (see Table 1);. Thus, the overall evaluable 
sample size for this report was 230 patients.  The median followup for the 
patient population is 2.96 years.
Of these 230 patients, 99 patients (cases) had severe late toxicity and 
131 patients (controls) did not have severe late toxicity. This results in 
a crude rate of late toxicity of 43%. It should be noted that if the entire 
population of patients (N=479) from all three studies are analyzed (as is 
often performed for studies of late effects) the crude rate would appear 
to be 21%., considerably lower than the data reported here. An actuarial 
plot of “Time to Severe Late Toxicity” for all 230 evaluable patients is 
shown in Figure 1.
for Case 230 174 143 81 36 17
Pts. at Risk
11
0
25
50
75
100
0 12 24 36 48 60 72
Months From Randomization
%
 F
ai
le
d
Figure 1. Time to  Severe Late Toxicity Events – All Evaluable Patients.
Table 2. Summary of patients with severe late toxicities (cases) 
and patients without severe late toxicities (controls)
Case Group
(n=99)
Control Group 
(n=131)
Age
 Median 60 56
 Range 33-78 26-78
 Age ≤  70 85  (86%) 118  (90%)
 Age >  70 14  (14%) 13  (10%)
Gender
 Male 78  (79%) 99  (76%)
. Female 21  (21%) 32  (24%)
Race
 Non-Black 90  (91%) 120  (92%)
 Black 9  (  9%) 11  (  8%)
KPS  
 60-80 24  (24%) 20  (15%)
 90-100 75  (76%) 111  (85%)
Hemoglobin  
 Median 14.3 14.2
 Range 7.1-18.2 9.9-18.2
 Hgb  ≤  13.5 gm/dl 28  (28%) 43  (33%)
 Hgb  >  13.5 gm/dl 71  (72%) 88  (67%)
Weight Loss in Previous 6 months (kg)  
 Mean 3.9 2.8
 ≤  5 kg 78  (79%) 112  (86%)
 >  5 kg 21  (21%) 19  (14%)
T Stage  
 T1/T2  18  (18%) 39  (30%)
 T3/T4 81  (82%) 92  (70%)
N Stage  
 NX/N0/N1 47  (47%) 63  (48%)
 N2 42  (42%) 58  (44%)
 N3 10  (10%) 10  (  8%)
Tumor Site  
 Oral cavity/oropharynx 42  (42%) 71  (54%)
  Oral Cavity 7    (7%) 5    (4%)
  Oropharynx 35  (35%) 66  (50%)
Larynx/hypopharynx  57  (58%) 60  (46%)
  Larynx 41  (41%) 51  (39%)
  Hypopharynx 16  (16%) 9     (7%)
Radiotherapy Dose-Intensity 
delivered (BED)  
 Mean 115 Gy 116 Gy
 Median 117 Gy 117 Gy
 Range 67-117 Gy 111-126 Gy
Neck Dissection after RT  
 Yes 26 (26%)* 21 (16%)
 No 73 (74%) 110 (84%)
Chemotherapy dose-intensity 
delivered  
 < 85% 22 (22%) 29 (22%)
 ≥ 85% 77 (78%) 102 (78%)
*Two of these patients had their neck dissection after experiencing a severe late toxicity
Table 3. Types of late toxicity events seen by trial
91-11 97-03 99-14 Total
Feeding Tube Dependence  —* 29*  29
> 2 yrs. Post RT 
Grade 3+ Pharyngeal  16 28 19 63
Dysfunction (RTOG late 
toxicity criteria)
Grade 3+ Laryngeal  22 6 0 28
Dysfunction (RTOG late 
toxicity criteria)
Death 11 9 2 22
Other (e.g. infection, fistula) 3 0 1 4
Any    38** 40** 21** 99**
No Severe late toxicity  50 62 19 13
event (controls)
   * Feeding tube data were not collected at all in RTOG 91-11.
** Numbers do not always add up along columns, due to some patients having more than one 
 toxicity event.
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The pre-treatment characteristics of these 230 patients are shown in Table 
2, including both pre-treatment and treatment-related characteristics. 
Table 3 shows an accounting of the types of late toxicity events observed 
in this analysis; most were related to swallowing function (particularly in 
RTOG 97-03 and RTOG 99-14) or laryngeal dysfunction (RTOG 91-11). 
Patients with severe toxicities (cases) were more likely to be older and/or 
to have larger T-stage and/or larynx/hypopharynx primary cancer. On 
univariate analysis, there were no statistically significant differences in 
the rates of late effects based on each individual study/arm.
Univariate logistic regression analysis of pre-treatment and treatment-
related variables is shown in Table 4. Actuarial estimates of time to 
severe late toxicity as a function of T-stage, primary tumor site, and 
neck dissection are shown in Figures 2a to 2c, respectively. The most 
significant pre-treatment factor associated with severe late toxicity was 
age, analyzed as a continuous variable (p=0.0038) – older patients were 
significantly more likely to have severe late toxicity. T-stage (T3-4 more 
likely to have severe late toxicity) and tumor site (larynx/hypopharynx 
more likely to have severe late toxicity) were also statistically significant 
factors. On univariate analysis, none of the treatment-related variables 
were statistically significant except BED (p<0.0001), with a paradoxical 
negative association between BED and severe late toxicity. The p-value 
for potential association between severe late toxicity and neck dissection 
after RT was 0.145.
The results of a multivariable logistic regression model analysis are 
shown in Table 4. Age, T-stage and tumor site remained statistically 
significant. In addition, a positive association between post-treatment 
neck dissection and severe late toxicity was noted (p=0.02). Specifically, 
out of the 230 patients in this study, 47 (20%) underwent post-treatment 
neck dissection; this included 22% of the oral cavity/oropharynx patients 
and 19% of the larynx/hypopharynx patients. These 47 patients had a 
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Figure 2b. Time to Severe Late Toxicity by Primary Tumor Site 
Larynx/Hypopharynx cancer is associated with a statistically
non-significant higher likelihood of severe late toxicity (p value 
from Gray’s Test =0.076). 
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Figure 2a. Time to Severe Late Toxicity by T stage Advanced T 
stage is associated with a higher likelihood of severe late toxicity 
(p value from Gray’s Test =0.031). 
Figure 2. Time to Severe Late Toxicity Subgoup Analyses based 
on Patient/Treatment Characteristics 
(All graphs exclude 2 patients who had neck dissection after already 
experiencing a severe late toxicity.) 
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Figure 2c. Time to Severe Late Toxicity by Neck Dissection 
Neck dissection is associated with a statistically non-significant 
higher likelihood of severe late toxicity (p-value from Gray’s 
Test =0.09).
RTOG Analysis
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crude rate of severe late toxicity of 55% (compared with 40% for the 183 
patients who did not undergo neck dissection).
Of note, besides neck dissection, other treatment-related factors were 
not associated with severe late effects. Although the most aggressive 
radiotherapy fractionation trial (RTOG 99-14, which used concomitant 
boost XRT + cisplatin) numerically had the highest crude rate of 
severe late toxicity (21/40 = 53%), there were no statistically significant 
differences among the trial arms.
As noted in Table 4, radiotherapy dose delivered (as analyzed as 
biologically equivalent dose [BED]) was significant on univariate analysis 
(with a paradoxical relationship in which lower RT dose was associated 
with higher risk) but fell out of the multivariable model.  The amount of 
chemotherapy delivered was not statistically significant in either model.
Discussion
This retrospective analysis of several prospective trials shows that the rate 
of severe late toxicity after CCRT for SCCHN is high, particularly with 
the analysis methodology used here. Specifically, in this study, patients 
with severe pre-treatment laryngopharynx dysfunction and patients 
with early tumor recurrence were excluded a priori from this analysis. 
Thus, the number of patients “at risk” for a severe late toxicity event 
is much smaller than the original treated population. This technique 
closely approximates the use of actuarial analysis of late complications, 
a technique which yields a higher rate of complications than simply 
reporting crude rate of complications, as reported by Bentzen et al.20 
A true actuarial analysis of late complications in head and neck cancer 
is difficult, because it is not easy to ascertain a date of onset of a late 
complication in any one individual patient (Figures 2a-2c). Our sample 
size of 230 patients makes this one of the largest studies of late toxicity in 
the concurrent chemoradiotherapy era. 
In this study, several factors that correlated with severe late toxicity were 
identified. Since this is a retrospective study, the data must be considered 
hypothesis-generating rather than definitive. Some caveats result from 
the fact that these studies were conducted over a 10-year time period 
(approximately 1991-2001), with variations in eligibility, treatment, and 
data collection techniques. A second problem inherent to retrospective 
studies like ours is that a number of potentially important factors may 
not have been collected at all. For example our database does not include 
information on tumor volume, cardiopulmonary co-morbidity, and 
amount of tobacco consumed in followup.
However, it is logical to believe that age, tumor site and tumor stage 
would predict for greater likelihood of severe late toxicity. The finding 
that post-treatment neck dissection was significantly associated with 
severe late toxicity was somewhat more surprising, although this has 
been reported previously. The number of patients undergoing post-
treatment neck dissection was relatively small (20%, despite over 50% 
of the patients having N2-3 disease), and thus these data can not be 
considered conclusive. It is possible that selection bias could lead to this 
association; for example, patients with larger volume neck disease may 
be more likely to undergo neck dissection and may be more likely to 
have neck-tumor-related damage to adjacent normal tissues unrelated 
to the neck dissection. It is possible, though, that disturbance of the soft 
tissues of the neck via post-treatment neck dissection could cause added 
swallowing dysfunction, for example by increasing fibrosis in the neck 
and thus limiting the mobility of the laryngopharynx. It should be noted 
that a similar report of an association between severe late toxicity and 
post-treatment neck dissection was recently reported by researchers at 
Table 4. Univariate and Multivariable Logistic Regression 
Models to Identify Covariates that are associated with 
severe late toxicity.
Univariate
Analysis
Multivariate
Analysis
Covariates
Odds
Ratio p-value
Odds 
Ratio
95% 
confidence 
Interval p value
Age 
 Continuous variable 1.043* 0.0038 1.05* [1.02,1.09] 0.001
Gender 
   Female RL
   Male 1.140 0.6846
Race 
   Non-Black RL
   Black 1.165 0.7458
KPS
   60-80 1.892 0.0612
   90-100 RL
Hemoglobin (gm%)
   Continuous Variable 1.005 0.9528
Weight loss (kg)
   Continuous Variable 1.018 0.3733
T Stage
   T1/T2 RL  RL
   T3/T4  2.041 0.0349 3.07 [1.444,6.54] 0.0036
N Stage
   NX/N0/N1 RL 
   N2 0.942 0.8464
   N3 1.297 0.6108
Tumor Site
   Oral cavity/oropharynx RL  RL
   Larynx/hypopharynx 2.955 0.0131 4.17 [1.57,11.03] 0.0041
BED (Toxicities) 
based on Actual 
Dose/Fx (Gy) 0.842 <0.0001
   Continuous Variable 
Neck dissection after RT**
   Yes 1.632 0.145 2.39 [1.16,4.92] 0.018
   No RL  RL
Percent of chemotherapy 
received relative to the 
protocol amount
   <  85% 1.033 0.9216
   ≥  85% RL
Abbreviations: RL=reference level; RT=radiation therapy
* The odds ratio of 1.043 for age indicates that for each one year increase in age, patients have 1.043 times 
higher odds of being in the case group (having a severe late toxicity) than being in the control group (not 
having a severe late toxicity).
** This excludes 2 patients who had neck dissection after having already experiencing a severe late toxicity.
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Fox Chase Cancer Center21.  If these findings are validated in additional, 
larger datasets, there may be important implications with respect to the 
controversy regarding neck dissection following chemoradiotherapy for 
patients with advanced neck disease.
The lack of significant association between cumulative radiotherapy dose 
delivery (or chemotherapy dose delivery) and severe late toxicity may 
be due to the narrow dose range prescribed and the generally excellent 
compliance. We are currently analyzing the detailed radiotherapy 
records (simulation films, dosimetry and treatment records) available at 
RTOG headquarters in order to estimate the doses received by individual 
normal tissue sub-structures within the head and neck. Several recent 
single-institution studies have rigorously analyzed the relationships 
between radiotherapy dose-volume-histograms for normal structures 
and the risk and severity of toxicities22, 23.
Considering the widespread acceptance of CCRT for SCCHN over the 
last 10 years, there are relatively few detailed studies of late toxicities. 
GORTEC reported long-term followup from their randomized trial of 
radiotherapy alone versus 5-FU/carboplatin/radiotherapy for oropharynx 
cancer; they did not find a significant difference in severe late toxicity24. 
However, there were fewer than 50 long-term survivors in that study. 
Staar reported that 51% of long-term survivors (> 2 years) after a very 
intense combination of accelerated fractionation radiotherapy and 
chemotherapy were dependent on feeding tubes8. With longer followup, 
that alarmingly high rate did decrease, and was not significantly worse 
than accelerated radiotherapy alone but the number of evaluable patients 
was relatively small25. Shiley reported that 4 of 13 (31%) cancer-free 
survivors (>1 year) after chemoradiotherapy required tube feedings for 
some or all of their nutrition26. 
These data suggest that the CCRT has reached the limits of acceptable 
long-term toxicity.  Dose intensity can not be easily increased without 
some new and effective technique(s) of protection against late effects. 
In the future, these may include modern techniques in radiotherapy 
technology27, 28, or biopharmacologic radioprotectors29-31. Presently, 
however, these techniques have only succeeded in reducing xerostomia, 
not severe late dysphagia. Emphasis should therefore be on careful 
patient selection for aggressive treatment and swallowing exercises before 
during and after radiotherapy32, 33.  Some patients may benefit from more 
invasive procedures, such as dilatation of hypopharyngeal/esophageal 
stricture under anesthesia.
For some patient subpopulations the risks of concurrent chemoradio-
therapy may outweigh the benefits. For example, subgroup analysis of a 
meta-analysis suggested that there was no significant survival benefit to 
CCRT in patients older than age 701. Our data may add to the controversy 
regarding management of the elderly patient with head and neck cancer 
– if there is no significant survival benefit and a significant increase in 
late toxicity with concurrent chemoradiotherapy, should it be the stan-
dard of care in this patient population?
Our study has several limitations that should be discussed. First, it is 
a “meta-analysis” of three separate clinical trials, each of which had 
somewhat different eligibility criteria, chemoradiotherapy regimen, and 
year of activation. However, all of the patients did receive treatment that 
would be considered appropriate standard of care in today’s oncology 
clinic. Second, our exclusion of patients with pre-existing severe 
laryngopharynx dysfunction from this analysis can be considered 
controversial. Although patients were excluded a priori, determining 
pre-existing severe laryngopharynx dysfunction is subjective. However, 
it should be noted that the determination of post-treatment severe 
laryngopharynx dysfunction (toxicity) is also subjective. It is extremely 
difficult to determine if severe dysfunction after treatment is the result of 
treatment or the result of the pre-existing cancer.  By excluding patients 
with pre-treatment severe laryngopharynx dysfunction, we attempted to 
isolate the influence of treatment on outcomes.  Third, our study is an 
exploratory analysis; while it is one of the larger series on late toxicity 
after chemoradiotherapy, the number of patients and number of events 
are relatively small. We plan to address this in the future with an analysis 
of the recently completed trial, RTOG 0129. This was a randomized trial 
of standard fractionation versus accelerated fractionation radiotherapy 
(with cisplatin in both arms). Preliminary acute and subacute toxicity 
data showed no significant differences between the two arms34. It is 
premature at this time to perform a detailed analysis of efficacy or late 
toxicity from that study. It is possible that with improved knowledge 
and experience with CCRT and supportive care available in the 21st 
century, outcomes may be improved in RTOG 0129 compared to
historical controls.
Ultimately, it should be remembered that for most patients with head 
and neck cancer, the highest priority is cure and length of survival35. 
Excessive concern about treatment toxicity should not prevent the use of 
proven aggressive multimodality treatment, provided the patient is well 
informed about the potential late sequelae of these aggressive treatment 
regimens.
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